ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019
Dassie Francesca
, Rosson Marco
, Parolin Matteo
, Russo Lucia
, Mazzocut Sara
, Martini Chiara
, De Carlo Eugenio
, Mioni Roberto
, Fallo Francesco
, Vettor Roberto
, Maffei Pietro
Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...